Q1 Earnings Forecast for CeriBell Issued By William Blair

CeriBell (NASDAQ:CBLL) – William Blair issued their Q1 2026 earnings per share (EPS) estimates for CeriBell in a research report issued on Wednesday, November 13th. William Blair analyst M. Andrew expects that the company will earn ($0.28) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for CeriBell’s current full-year earnings is ($1.55) per share. William Blair also issued estimates for CeriBell’s Q2 2026 earnings at ($0.25) EPS and Q3 2026 earnings at ($0.24) EPS.

A number of other equities analysts have also recently issued reports on CBLL. TD Cowen began coverage on CeriBell in a report on Tuesday, November 5th. They set a “buy” rating and a $31.00 target price on the stock. Canaccord Genuity Group started coverage on CeriBell in a research report on Tuesday, November 5th. They set a “buy” rating and a $30.00 price target for the company. Canaccord Genuity Group lifted their target price on shares of CeriBell from $30.00 to $31.00 and gave the stock a “buy” rating in a report on Wednesday. JPMorgan Chase & Co. started coverage on CeriBell in a research report on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 price target on the stock. Finally, Bank of America initiated coverage on CeriBell in a research note on Tuesday, November 5th. They set a “buy” rating and a $32.00 target price for the company. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $31.20.

CeriBell Stock Down 3.7 %

Shares of NASDAQ:CBLL opened at $26.53 on Friday. CeriBell has a twelve month low of $23.00 and a twelve month high of $29.53.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($1.03). The firm had revenue of $17.20 million for the quarter, compared to analyst estimates of $17.06 million.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.